U.S. sales of Pfizer’s Comirnaty shots have taken a nosedive since the Trump administration updated its immunization schedules last month and dropped the universal collective recommendations for COVID-19 vaccines.
The pharmaceutical company’s revenues for the third quarter of 2025 are down 6% — amounting to a $1 billion drop — compared to the same stretch the previous year.
‘CDC’s 2022 blanket recommendation for perpetual COVID-19 boosters deterred health care providers from talking about the risks.’
Pfizer indicated in its latest earnings statement that “the operational decrease was primarily driven by a year-over-year decline in COVID-19 product revenues largely due to lower infection rates impacting Paxlovid demand as well as a narrower vaccine recommendation for COVID-19 in the U.S. that reduced the eligible population for Comirnaty.”
Trending: WATCH: MASSIVE Hongqi Bridge In China Collapses Into Mountain! 758 meters long
Sales of Comirnaty were
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!